{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:58:37Z","timestamp":1761170317209,"version":"build-2065373602"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95105","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:04:57Z","timestamp":1761098697000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Central Nervous System Lymphoma Associated With Immune Deficiency and Dysregulation: Challenges in Treatment and Management"],"prefix":"10.7759","author":[{"given":"Yuki","family":"Dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Kunieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13150-4_13","article-title":"Post-transplant lymphoproliferative disorders","volume":"165","author":"Singavi AK","year":"2015","unstructured":"Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res. 2015, 165:305-27. 10.1007\/978-3-319-13150-4_13","journal-title":"Cancer Treat Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001991","article-title":"A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation (Article in Japanese)","volume":"64","author":"Otsuka H","year":"2024","unstructured":"Otsuka H, Shima T, Yoshida K, Kurohama H, Tsujino A. A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation (Article in Japanese). Rinsho Shinkeigaku. 2024, 64:794-801. 10.5692\/clinicalneurol.cn-001991","journal-title":"Rinsho Shinkeigaku"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans CP","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, et al.. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004, 103:275-82. 10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14465","article-title":"Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients","volume":"18","author":"Mahale P","year":"2018","unstructured":"Mahale P, Shiels MS, Lynch CF, Engels EA. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant. 2018, 18:453-61. 10.1111\/ajt.14465","journal-title":"Am J Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24834","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"116","author":"Cavaliere R","year":"2010","unstructured":"Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010, 116:863-70. 10.1002\/cncr.24834","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens AM","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR, et al.. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013, 13:1512-22. 10.1111\/ajt.12211","journal-title":"Am J Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12568","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder following kidney transplantation: a multi-institution study in Japan over 30 years","volume":"21","author":"Ishihara H","year":"2017","unstructured":"Ishihara H, Okumi M, Tanabe K. Primary central nervous system post-transplant lymphoproliferative disorder following kidney transplantation: a multi-institution study in Japan over 30 years. Ther Apher Dial. 2017, 21:516-8. 10.1111\/1744-9987.12568","journal-title":"Ther Apher Dial"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.007","article-title":"B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry","volume":"61","author":"Sundin A","year":"2017","unstructured":"Sundin A, Grzywacz BJ, Yohe S, Linden MA, Courville EL. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. Hum Pathol. 2017, 61:140-7. 10.1016\/j.humpath.2016.12.007","journal-title":"Hum Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12812","article-title":"Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma","volume":"106","author":"Okamoto A","year":"2015","unstructured":"Okamoto A, Yanada M, Miura H, et al.. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. Cancer Sci. 2015, 106:1576-81. 10.1111\/cas.12812","journal-title":"Cancer Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0726-6","article-title":"Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential","volume":"10","author":"White ML","year":"2019","unstructured":"White ML, Moore DW, Zhang Y, Mark KD, Greiner TC, Bierman PJ. Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential. Insights Imaging. 2019, 10:46. 10.1186\/s13244-019-0726-6","journal-title":"Insights Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita Y","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, et al.. Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021, 23:122-33. 10.1093\/neuonc\/noaa145","journal-title":"Neuro Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04548-2","article-title":"Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry","volume":"100","author":"Zimmermann H","year":"2021","unstructured":"Zimmermann H, Nitsche M, Pott C, et al.. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Ann Hematol. 2021, 100:2043-50. 10.1007\/s00277-021-04548-2","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416970-primary-central-nervous-system-lymphoma-associated-with-immune-deficiency-and-dysregulation-challenges-in-treatment-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:05:00Z","timestamp":1761098700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416970-primary-central-nervous-system-lymphoma-associated-with-immune-deficiency-and-dysregulation-challenges-in-treatment-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.95105","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}